Azithromycin - Antimicrobe.org
... Otitis media, acute (> 6 months): 30mg/kg PO x 1, or 10mg/kg PO q24h x 3 days, or 10 mg/kg PO on day 1 followed by 5 mg/kg PO q24h on days 2-5 Pharyngitis, tonsillitis (>2 years old): 12 mg/kg PO q24h x 5 days Pharyngitis/tonsillitis (second-line therapy): (>16 years) 500 mg PO day 1, then 250 mg q2 ...
... Otitis media, acute (> 6 months): 30mg/kg PO x 1, or 10mg/kg PO q24h x 3 days, or 10 mg/kg PO on day 1 followed by 5 mg/kg PO q24h on days 2-5 Pharyngitis, tonsillitis (>2 years old): 12 mg/kg PO q24h x 5 days Pharyngitis/tonsillitis (second-line therapy): (>16 years) 500 mg PO day 1, then 250 mg q2 ...
Sodium chloride 0.45%/Half-normal saline
... muscle and heart abnormalities. Signs may include weakness, constipation, rapid breathing, and increased heart rate. Overhydration may also cause fluid to accumulate in the lungs (pulmonary edema) and increase the workload for the heart. Signs may include increased or rapid breathing, coughing, or w ...
... muscle and heart abnormalities. Signs may include weakness, constipation, rapid breathing, and increased heart rate. Overhydration may also cause fluid to accumulate in the lungs (pulmonary edema) and increase the workload for the heart. Signs may include increased or rapid breathing, coughing, or w ...
Adult Asthma - NHS Lothian Respiratory Managed Clinical Network
... GLOBAL INITIATIVE FOR ASTHMA, GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE ...
... GLOBAL INITIATIVE FOR ASTHMA, GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE ...
Oral Medications in Optometric Practice
... • Step 1. Convert pounds to kg: 22 lb × 1 kg/2.2 lb = 10 kg • Step 2. Calculate the dose in mg: 10 kg × 25 mg/kg/day = 250 mg/day • Step 3. Divide the dose by the frequency: 250 mg/day ÷ 2 (BID) = 125 mg/dose BID • Step 4. Convert the mg dose to mL: 125 mg/dose ÷ 125 mg/5 mL = 5.0 mL BID ...
... • Step 1. Convert pounds to kg: 22 lb × 1 kg/2.2 lb = 10 kg • Step 2. Calculate the dose in mg: 10 kg × 25 mg/kg/day = 250 mg/day • Step 3. Divide the dose by the frequency: 250 mg/day ÷ 2 (BID) = 125 mg/dose BID • Step 4. Convert the mg dose to mL: 125 mg/dose ÷ 125 mg/5 mL = 5.0 mL BID ...
Psy 5260 – Summer I 2009 Week Seven Lecture Notes
... cognitive impairments (in females, weight gain, polycystic ovaries, increased androgens) Potential toxicities: liver, pancreas, also teratogenic ...
... cognitive impairments (in females, weight gain, polycystic ovaries, increased androgens) Potential toxicities: liver, pancreas, also teratogenic ...
MV4-11
... FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML) and therefore an attractive target for novel therapies1 However, limited long-term efficacy of FLT3 inhibitors in clinical development may indicate the need to target other key drivers of the disease Cyclin-dependent kinases 1, ...
... FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML) and therefore an attractive target for novel therapies1 However, limited long-term efficacy of FLT3 inhibitors in clinical development may indicate the need to target other key drivers of the disease Cyclin-dependent kinases 1, ...
Narcotics and OD`s Uppsala University, Sweden, November 25th
... In the absence of alternatives: maybe the new Adapt device will be acceptable? However the panel warned that the high dose could cause unwanted reactions also involving heart attacks, seizures - particular in Methadone intoxicated patients – and severe violence and anger when using the Adapt device ...
... In the absence of alternatives: maybe the new Adapt device will be acceptable? However the panel warned that the high dose could cause unwanted reactions also involving heart attacks, seizures - particular in Methadone intoxicated patients – and severe violence and anger when using the Adapt device ...
Memorandum 1 18 4 '03 MAR 13 PC48 s.
... from common cold and cough, and bronchitis. Steu down armroach Asmakure has been designed in such a way so as to ensure assured result with sustained use of the prescribed dosage which brings down even the steroid taking patients to the level of normal breathing and tranquility. Regular use of Asmak ...
... from common cold and cough, and bronchitis. Steu down armroach Asmakure has been designed in such a way so as to ensure assured result with sustained use of the prescribed dosage which brings down even the steroid taking patients to the level of normal breathing and tranquility. Regular use of Asmak ...
psychopharmacology_2.. - University of Washington
... Long half life and active metabolite may build up (e.g. not a good choice in patients with hepatic illness) Significant P450 interactions so this may not be a good choice in pts already on a number of meds Initial activation may increase anxiety and insomnia More likely to induce mania than some of ...
... Long half life and active metabolite may build up (e.g. not a good choice in patients with hepatic illness) Significant P450 interactions so this may not be a good choice in pts already on a number of meds Initial activation may increase anxiety and insomnia More likely to induce mania than some of ...
Prescribing Information
... Increase in Serum Calcium Patients randomized to RAYALDEE experienced a greater mean (SE) increase in serum calcium (P<0.001) than patients randomized to placebo [i.e., 0.2 (0.02) mg/dL on RAYALDEE versus 0.1 (0.03) mg/dL on placebo from baseline to trial end]. Six subjects (2%) in the RAYALDEE trea ...
... Increase in Serum Calcium Patients randomized to RAYALDEE experienced a greater mean (SE) increase in serum calcium (P<0.001) than patients randomized to placebo [i.e., 0.2 (0.02) mg/dL on RAYALDEE versus 0.1 (0.03) mg/dL on placebo from baseline to trial end]. Six subjects (2%) in the RAYALDEE trea ...
Actos - DavisPlus - FA Davis Company
... Contraindicated in: Hypersensitivity; Type 1 diabetes; Diabetic ketoacidosis; Clinical evidence of active liver disease orqALT (⬎2.5 times upper limit of normal); ⫽ Canadian drug name. ...
... Contraindicated in: Hypersensitivity; Type 1 diabetes; Diabetic ketoacidosis; Clinical evidence of active liver disease orqALT (⬎2.5 times upper limit of normal); ⫽ Canadian drug name. ...
Rescue medication
... infusions and patients will be asked if they experience discomfort during the infusion. In addition, patients will be asked daily during treatment and at each visit during follow up if they have suffered any side-effects or adverse events (AE). Electrocardiograms (ECG) will be performed where clinic ...
... infusions and patients will be asked if they experience discomfort during the infusion. In addition, patients will be asked daily during treatment and at each visit during follow up if they have suffered any side-effects or adverse events (AE). Electrocardiograms (ECG) will be performed where clinic ...
First Dose in Humans
... potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005) ...
... potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005) ...
Urinary Antiseptics
... Used in chronic UTI where eradication of infection by short term systemic therapy has not been possible ...
... Used in chronic UTI where eradication of infection by short term systemic therapy has not been possible ...
10117sgp10
... At the center, from May 25, 2004, to May 4, 2005, 119 patients whose disease was resistant to imatinib were enrolled. The patients were assigned to receive daily doses of nilotinib according to the following dosing schedule: 50 mg (7 patients), 100 mg (7), 200 mg (10), 400 mg (10), 600 mg (6), 800 m ...
... At the center, from May 25, 2004, to May 4, 2005, 119 patients whose disease was resistant to imatinib were enrolled. The patients were assigned to receive daily doses of nilotinib according to the following dosing schedule: 50 mg (7 patients), 100 mg (7), 200 mg (10), 400 mg (10), 600 mg (6), 800 m ...
Document
... SO, I double the dose and the plasma concentrations double (I get what I expect). The pharmacokinetics PREDICT that I when I double the dose the concentrations double so THE PHARMACOKINETICS are dose independent. ...
... SO, I double the dose and the plasma concentrations double (I get what I expect). The pharmacokinetics PREDICT that I when I double the dose the concentrations double so THE PHARMACOKINETICS are dose independent. ...
Drug Information Sheet("Kusuri-no-Shiori") Internal Revised: 07
... ・chest pain, palpitation, chest discomfort [QT prolongation, ventricular tachycardia (incl. Torsades de pointes), ventricular fibrillation] ・lassitude, muscle pain, brown urine [rhabdomyolysis] ・convulsion [convulsion] ・purpura [allergic purpura] ・rash, fever [drug-induced hypersensitivity syndrome] ...
... ・chest pain, palpitation, chest discomfort [QT prolongation, ventricular tachycardia (incl. Torsades de pointes), ventricular fibrillation] ・lassitude, muscle pain, brown urine [rhabdomyolysis] ・convulsion [convulsion] ・purpura [allergic purpura] ・rash, fever [drug-induced hypersensitivity syndrome] ...
Effective Shared Care Agreement (ESCA) for
... with Parkinson’s disease who have frequent and/or severe akinesia (“off periods”) not controlled by levodopa or other dopamine agonists. Research has shown that Apomorphine reduces the daily “off” period time by up to 80% in patients with latestage Parkinson’s disease associated with refractory on-o ...
... with Parkinson’s disease who have frequent and/or severe akinesia (“off periods”) not controlled by levodopa or other dopamine agonists. Research has shown that Apomorphine reduces the daily “off” period time by up to 80% in patients with latestage Parkinson’s disease associated with refractory on-o ...
Management of Non-Insulin Dependent Diabetes Mellitus
... Flatulence, bloating, abdominal pain and diarrhoea are common and are due to undigested carbohydrate in the bowel. Starting with a low dose (50mg bd) and increasing gradually to the maximum dose (200mg tds) will minimise GI side effects.11,42 Only 1% of acarbose is absorbed systemically and so other ...
... Flatulence, bloating, abdominal pain and diarrhoea are common and are due to undigested carbohydrate in the bowel. Starting with a low dose (50mg bd) and increasing gradually to the maximum dose (200mg tds) will minimise GI side effects.11,42 Only 1% of acarbose is absorbed systemically and so other ...
Guidelines for use of Digoxin (Lanoxin )
... individualized to patient; if so, notify H.O., check last level result and hold medication 5. Monitor for dysrhythmias; respiratory congestion; peripheral edema 6. Monitor daily weights and perform accurate I & O 7. Order must be taken off by two RNs 8. Obtain periodic EKGs to assess both desired ef ...
... individualized to patient; if so, notify H.O., check last level result and hold medication 5. Monitor for dysrhythmias; respiratory congestion; peripheral edema 6. Monitor daily weights and perform accurate I & O 7. Order must be taken off by two RNs 8. Obtain periodic EKGs to assess both desired ef ...
High Dose Colistimethate Sodium (Colistin)
... infections caused by pathogens with minimum inhibitory concentration (MIC) higher than 0·5 mg/L. Recent studies have shown that high dose regimens are more effective with limited increase in irreversible nephrotoxicity.1 Many patients do experience nephrotoxicity but the majority recover renal funct ...
... infections caused by pathogens with minimum inhibitory concentration (MIC) higher than 0·5 mg/L. Recent studies have shown that high dose regimens are more effective with limited increase in irreversible nephrotoxicity.1 Many patients do experience nephrotoxicity but the majority recover renal funct ...
corticosteroids - Crohn`s and Colitis Foundation of America
... Corticosteroids (often referred to simply as steroids but are not to be confused with body-building “steroids”) were first introduced as therapy for IBD in the 1950s. Since that time, these powerful and fast-acting anti-inflammatory drugs have been frequently used in the treatment of acute flare-ups ...
... Corticosteroids (often referred to simply as steroids but are not to be confused with body-building “steroids”) were first introduced as therapy for IBD in the 1950s. Since that time, these powerful and fast-acting anti-inflammatory drugs have been frequently used in the treatment of acute flare-ups ...
- Celon Pharma
... The objective of the CELONKO project is preclinical and clinical development of a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs). As a result of R&D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight agains ...
... The objective of the CELONKO project is preclinical and clinical development of a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs). As a result of R&D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight agains ...
Neo-Mercazole
... of replacing Neo-Mercazole with propylthiouracil should furthermore be taken into consideration, since this antithyroid drug has not resulted so far in any thyroid modifications at all in the unborn child. Some authors prefer surgical treatment. Therefore, Neo-Mercazole should be used in pregnancy o ...
... of replacing Neo-Mercazole with propylthiouracil should furthermore be taken into consideration, since this antithyroid drug has not resulted so far in any thyroid modifications at all in the unborn child. Some authors prefer surgical treatment. Therefore, Neo-Mercazole should be used in pregnancy o ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.